Agenix settles Synbiotics litigation
28 June, 2004 by Melissa TrudingerAgenix (ASX: AGX) subsidiary Agen Biomedical has agreed to settle its litigation with its former US distributor Synbiotics over alleged infringements of Synbiotics' canine heartworm diagnostics and related supply contract issues.
BioTech Capital takes punt on meditech firm
28 June, 2004 by Renate KrelleSydney-based pooled development fund BioTech Capital (ASX:BTC) has dipped its toe into the medical device sector with a $2 million investment in Continence Control Systems (CCS).
Avastra shares slump below float price
25 June, 2004 by Renate KrelleSydney-based biotechnology company Avastra (ASX: AVS) has turned in one of the poorest performances amongst recent biotech IPOs, after listing without fanfare earlier this week. In their Wednesday debut, Avastra shares dropped below their AUD$1.00 issue price to close at $0.85. At time of writing, they had slumped further to AUD$0.72.
Imugene unveils details of piglet product
25 June, 2004 by Graeme O'NeillNorth Ryde animal-health biopharma Imugene Limited (ASX:IMU) is fast-tracking the commercialisation of its recently acquired receptor mimic technology (RMT).
Anadis seals Tartura milk partnership
25 June, 2004 by Graeme O'NeillMelbourne biopharma Anadis (ASX:ANX) has signed an agreement with its long-time collaborator Tatura Milk Industries (TMI) that will secure its supply of antibody-rich colostrum from cows vaccinated with its patented vaccines.
Sixth Ventracor device implanted
24 June, 2004 by Renate KrelleThe sixth patient in Ventracor's (ASX:VCR) pilot trial has been implanted with the company's 'VentrAssist' left ventricular assistance device at The Alfred hospital in Melbourne.
Prostate-of-the-art tomato
24 June, 2004 by Graeme O'NeillIt’s deep red, juicy, tastes superb and should protect slightly less than 50 per cent of consumers against one of the most common of all cancers. And it’s not genetically modified.
Biotron's Vpu blockers clear first hurdle
24 June, 2004 by Graeme O'NeillCanberra-based anti-viral drug developer Biotron has completed acute toxicity tests of its lead anti-HIV drug candidates in mice and found their toxicity levels are within acceptable limits.
Bionomics presents new anti-angiogenesis evidence
24 June, 2004 by Graeme O'NeillAdelaide biotech Bionomics (ASX:BNO, BNOOA, US OTC:BMICY) will present new evidence for the therapeutic promise of several molecular antagonists for its proprietary drug target BNO69 in the US today.
Xenome gets IND green light and $2 million
23 June, 2004 by Renate KrelleThe US Food and Drug Administration has approved Brisbane-based Xenome’s Investigational New Drug (IND) submission for its Xen2174 pain killer.
Austcancer's Galenica acquisition finalised
23 June, 2004 by Renate KrelleAustralian Cancer Technology ("AustCancer") (ASX:ACU) has finalised due diligence on its US$5 million acquisition of Alabama-based vaccine developer Galenica Pharmaceuticals.
Life Therapeutics aims for Nasdaq
22 June, 2004 by Renate KrelleLife Therapeutics -- formerly known as Gradipore (ASX:GDP) -- is aiming toestablish a Level 1 American Depository Receipt (ADR) program, in readiness for a Nasdaq.
US biotech IPOs falter as price targets cut
21 June, 2004 by Staff WritersThe outlook for biotech IPOs dimmed further last Friday, as Senomyx cut the price of its offering for the second time in as many days and Momenta Pharmaceuticals reducing its estimated price range.
Bionomics epilepsy test to be commercialised after trial
21 June, 2004 by Graeme O'NeillAdelaide epilepsy specialist Bionomics (ASX:BNO) has validated its promising genetic test for severe myoclonic epilepsy of infancy (SMEI) by successfully screening a large cohort of children diagnosed with severe epilepsy.
Japanese pharma courts Pacific Edge
21 June, 2004 by Graeme O'NeillNew Zealand cancer prognostics company Pacific Edge Biotechnology appears close to securing multi-million dollar investments from several big Japanese pharmaceutical companies.
